

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fraser W. SCOTT, *et al.*

Serial No.: 10/597,034

Filed: October 3, 2006

For: DIABETOGENIC EPITOPES

Conf. No.: 5076

Art Unit: 1644

Examiner: Gerald R. EWOLDT

Atty. Dckt: 034205.003 (08899427US1)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Listed on the accompanying PTO SB-08a Form are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. § 1.56, 1.97 and 1.98. **A copy of the listed reference was previously submitted on July 7, 2006.** Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application.

*Applicants respectfully submit that WO 01/24793 A2 was previously provided in a prior Information Disclosure Statement, however, the SB-08a form had a typographical error and listed the document as WO 01/25793 A2. Thus, the enclosed SB-08a form alleviates this typographical error.*

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

Respectfully submitted,

/Suzannah K. Sundby/

Suzannah K. Sundby

Registration No. 43,172

Date: 10 June 2009

SMITH, GAMBRELL & RUSSELL, LLP

1130 Connecticut Avenue, N.W., Suite 1130

Washington, D.C. 20036

Telephone: (202) 263-4332

Fax: (202) 263-4352

ssundby@sgrlaw.com